FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Kris

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Mutation

Co-author Network

Publications

TOP 3
Natasha Rekhtman; Camelia S Sima; Laura J Tafe; William D Travis; Lu Wang; Maureen F Zakowski; Maria E Arcila; Jamie E Chaft; Agnes Colanta; Mark G Kris; Andre L Moreira; Marc Ladanyi
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Helena A Yu; Andreas Rimner; Naiyer A Rizvi; Camelia S Sima; Stephen B Solomon; Christopher G Azzoli; James Huang; Mark G Kris; Lee M Krug; Vincent A Miller; Paul Paik; Maria C Pietanza; Gregory J Riely
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Maria E Arcila; Jamie E Chaft; Mark G Kris; Christopher Lau; Khedoudja Nafa; Natasha Rekhtman; Boris A Reva; Maureen F Zakowski; Marc Ladanyi
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Kris (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Natasha Rekhtman; Camelia S Sima; Laura J Tafe; William D Travis; Lu Wang; Maureen F Zakowski; Maria E Arcila; Jamie E Chaft; Agnes Colanta; Mark G Kris; Andre L Moreira; Marc Ladanyi
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013;26(4):511-22.
2013: Helena A Yu; Andreas Rimner; Naiyer A Rizvi; Camelia S Sima; Stephen B Solomon; Christopher G Azzoli; James Huang; Mark G Kris; Lee M Krug; Vincent A Miller; Paul Paik; Maria C Pietanza; Gregory J Riely
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(3):346-51.
2013: Maria E Arcila; Jamie E Chaft; Mark G Kris; Christopher Lau; Khedoudja Nafa; Natasha Rekhtman; Boris A Reva; Maureen F Zakowski; Marc Ladanyi
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Molecular cancer therapeutics 2013;12(2):220-9.
2013: Melissa L Johnson; Mark G Kris; Marc Ladanyi; Paul K Paik; William Pao; Jamie Chaft; Camelia S Sima; Gregory J Riely
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Cancer 2013;119(2):356-62.
2013: Anna M Varghese; Jamie E Chaft; Melissa L Johnson; Marc Ladanyi; Gregory J Riely; Camelia S Sima; Mark G Kris
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(1):123-5.
2012: Paul K Paik; Camelia S Sima; Daphne Ang; Sandra P D'Angelo; Snjezana Dogan; Melissa L Johnson; Mark G Kris; Marc Ladanyi; Vincent A Miller; Gregory J Riely
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Cancer 2012;118(23):5840-7.
2012: Snjezana Dogan; Melissa L Johnson; Mark G Kris; Paul K Paik; Gregory J Riely; Ronglai Shen; Maureen F Zakowski; Daphne C Ang; Edyta B Brzostowski; Sandra P D'Angelo; Marc Ladanyi
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(22):6169-77.
2012: Paul K Paik; Mark G Kris; Marc Ladanyi; Andre L Moreira; Camelia S Sima; Anna M Varghese; Natasha Rekhtman
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Molecular cancer therapeutics 2012;11(11):2535-40.
2012: Maria E Arcila; Jamie E Chaft; Mark G Kris; Christopher Lau; Khedoudja Nafa; Paul K Paik; Sinchita Roy-Chowdhuri; Michael Zaidinski; Maureen F Zakowski; Marc Ladanyi
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(18):4910-8.
2012: Maria C Pietanza; Katharine A Price; Gregory J Riely; Kendrith M Rowland; Ravi Salgia; Margaret Tonda; Michael S Wertheim; Christopher G Azzoli; Jan H Beumer; Afshin Dowlati; Shirish M Gadgeel; Mark G Kris; Lee M Krug; Thomas J Lynch; Vincent A Miller; Ben Mitchell; Naiyer A Rizvi
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(5):856-65.
2012: Mai He; Pasi A Janne; Mark G Kris; Marc Ladanyi; Vincent A Miller; Khedoudja Nafa; Maria E Arcila; Marzia Capelletti; Michael J Eck; Michelle S Ginsberg; Cai-Hong Yun; Binsheng Zhao; Geoffrey R Oxnard
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1790-7.
2012: Katharine Lampen-Sachar; Chaya S Moskowitz; Naiyer A Rizvi; Lawrence H Schwartz; Maureen F Zakowski; Binsheng Zhao; Junting Zheng; Mark G Kris; Michelle S Ginsberg
Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas.
Lung cancer (Amsterdam, Netherlands) 2012;75(3):332-5.
2012: Natasha Rekhtman; Laura J Tafe; William D Travis; Maureen F Zakowski; Maria E Arcila; Mark G Kris; Andre L Moreira; Geoffrey R Oxnard; Paul K Paik; Marc Ladanyi
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1167-76.
2012: Juliann Chmielecki; Katherine Hutchinson; Mark G Kris; Vincent Miller; M Catherine Pietanza; Naiyer Rizvi; Ronglai Shen; Thomas Stout; Agnes Viale; Zhiguo Zhao; Dana Aftab; Xi Chen; William Pao
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(2):434-42.
2012: Jamie E Chaft; Maria E Arcila; Marc Ladanyi; Christopher Lau; Paul K Paik; Maria C Pietanza; Gregory J Riely; Valerie Rusch; Camelia S Sima; Maureen F Zakowski; Mark G Kris
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Molecular cancer therapeutics 2012;11(2):485-91.
2011: Christian Grommes; Andrei I Holodny; Mark G Kris; Vincent A Miller; Geoffrey R Oxnard; William Pao; Jennifer L Clarke; Andrew B Lassman
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Neuro-oncology 2011;13(12):1364-9.
2011: Paul K Paik; Maria C Pietanza; Naiyer A Rizvi; Charles Rudin; Sara Subzwari; Naoko Takebe; William Travis; Leslie Tyson; Andrew Brown; Michelle S Ginsberg; Leonard James; Rosalyn A Juergens; Mark G Kris; Susan Markus; Lee M Krug
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2011;74(3):481-5.
2011: Ethan Basch; Paul J Hesketh; Mark G Kris; Ann Alexis Prestrud; Sarah Temin; Gary H Lyman
Antiemetics: american society of clinical oncology clinical practice guideline update.
Journal of oncology practice / American Society of Clinical Oncology 2011;7(6):395-8.
2011: Ethan Basch; Maurice Chesney; Rebecca A Clark-Snow; Petra Feyer; Anne Marie Flaherty; Barbara Freundlich; Paul J Hesketh; Mark G Kris; Gary H Lyman; Gary Morrow; Ann Alexis Prestrud; Kamakshi V Rao; Rowena N Schwartz; Mark R Somerfield
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(31):4189-98.
2011: Christopher G Azzoli; Megan Dunne; Michelle Ginsberg; Martha Huntington; Leonard James; Mark G Kris; Lee M Krug; Jennifer May; Vincent Miller; Jyoti D Patel; Michael Saunders; Sara Subzwari; Leslie Tyson; Francis M Sirotnak
Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(11):1915-22.
2011: Paul K Paik; Gregory J Riely; Camelia S Sima; Christopher G Azzoli; Robert T Heelan; Leonard P James; Mark G Kris; Vincent A Miller; Erin Moore; Kenneth K Ng; Naiyer A Rizvi
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.
Cancer chemotherapy and pharmacology 2011;68(5):1331-7.
2011: Stephen A Barnett; Robert J Downey; Manjit S Bains; Bernard J Park; Gabriel Plourde; Nabil P Rizk; Valerie W Rusch; Ronglai Shen; Junting Zheng; Mark G Kris
Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(9):1530-6.
2011: Geoffrey R Oxnard; Lawrence H Schwartz; Camelia S Sima; Binsheng Zhao; Michelle S Ginsberg; Pingzhen Guo; Leonard P James; Mark G Kris; Robert A Lefkowitz; Gregory J Riely
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(23):3114-9.
2011: Gregory J Riely; Naiyer A Rizvi; Christopher G Azzoli; Melissa L Johnson; Mark G Kris; Lee M Krug; Chanoa Medina; Vincent A Miller; William Pao; Maria C Pietanza; Michelle S Ginsberg
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(8):1435-7.
2011: Juliann Chmielecki; Elisa de Stanchina; Jasmine Foo; Michelle S Ginsberg; Katherine Hutchinson; Akira Inoue; Mark G Kris; Marc Ladanyi; Franziska Michor; Vincent A Miller; Kadoaki Ohashi; Geoffrey R Oxnard; Nicholas D Socci; Romel Somwar; Martin L Sos; Roman K Thomas; Agnes Viale; Lu Wang; Katherine R Amato; Maria Arcila; William Pao
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Science translational medicine 2011;3(90):90ra59.
2011: Melissa L Johnson; Gregory J Riely; Naiyer A Rizvi; Christopher G Azzoli; Mark G Kris; Camelia S Sima; Michelle S Ginsberg; William Pao; Vincent A Miller
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(6):1128-31.
2011: Paul K Paik; Maria E Arcila; Michael Fara; Camelia S Sima; Vincent A Miller; Mark G Kris; Marc Ladanyi; Gregory J Riely
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2046-51.
2011: Sandra P D'Angelo; Maria C Pietanza; Melissa L Johnson; Gregory J Riely; Vincent A Miller; Camelia S Sima; Maureen F Zakowski; Valerie W Rusch; Marc Ladanyi; Mark G Kris
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2066-70.
2011: Sandra P D'Angelo; Mark G Kris; Maria C Pietanza; Naiyer A Rizvi; Christopher G Azzoli
A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(3):624-6.
2011: Mark G Kris; Maurizio Tonato; Emilio Bria; Enzo Ballatori; Birgitte Espersen; Jørn Herrstedt; Cynthia N Rittenberg; Lawrence H Einhorn; Steven M Grunberg; Mitsue Saito; Gary Morrow; Paul J Hesketh
Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19 Suppl 1():S25-32.
2011: Sandra P D'Angelo; Bernard Park; Christopher G Azzoli; Mark G Kris; Valerie Rusch; Marc Ladanyi; Maureen F Zakowski
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
The Journal of thoracic and cardiovascular surgery 2011;141(2):476-80.
2011: J Matthew Reinersman; Melissa L Johnson; Gregory J Riely; Dhananjay A Chitale; Anthony D Nicastri; Gerald A Soff; Ann Grossbart Schwartz; Camelia S Sima; Getinet Ayalew; Christopher Lau; Maureen F Zakowski; Valerie W Rusch; Marc Ladanyi; Mark G Kris
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(1):28-31.
2010: Kevin C De Braganca; Yelena Janjigian; Christopher G Azzoli; Mark G Kris; Maria C Pietanza; Craig P Nolan; Antonio M P Omuro; Andrei I Holodny; Andrew B Lassman
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.
Journal of neuro-oncology 2010;100(3):443-7.
2010: David S Ettinger; Wallace Akerley; Gerold Bepler; Matthew G Blum; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; David H Johnson; Anne Kessinger; Ritsuko Komaki; Fengming P Kong; Mark G Kris; Lee M Krug; Quynh-Thu Le; Inga T Lennes; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Scott J Swanson; Douglas E Wood; Stephen C Yang
Thymic malignancies.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(11):1302-15.
2010: Paul K Paik; Charles Rudin; Andrew Brown; Naiyer A Rizvi; Naoko Takebe; William D Travis; Leonard James; Michelle S Ginsberg; Rosalyn A Juergens; Susan Markus; Leslie Tyson; Sara Subzwari; Mark G Kris; Lee M Krug
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Cancer chemotherapy and pharmacology 2010;66(6):1079-85.
2010: Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(10):1623-9.
2010: Binsheng Zhao; Geoffrey R Oxnard; Chaya S Moskowitz; Mark G Kris; William Pao; Pingzhen Guo; Valerie M Rusch; Marc Ladanyi; Naiyer A Rizvi; Lawrence H Schwartz
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(18):4647-53.
2010: Nicolas Girard; Julie Teruya-Feldstein; Eden C Payabyab; Gregory J Riely; Valerie W Rusch; Mark G Kris; Maureen F Zakowski
Insulin-like growth factor-1 receptor expression in thymic malignancies.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(9):1439-46.
2010: David S Ettinger; Wallace Akerley; Gerold Bepler; Matthew G Blum; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Apar Kishor P Ganti; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; Mohammad Jahanzeb; David H Johnson; Anne Kessinger; Ritsuko Komaki; Fengming P Kong; Mark G Kris; Lee M Krug; Quynh-Thu Le; Inga T Lennes; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; George R Simon; Scott J Swanson; Douglas E Wood; Stephen C Yang
Non-small cell lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(7):740-801.
2010: Wee-Lee Yeo; Gregory J Riely; Beow Y Yeap; Michelle W Lau; Jeremy L Warner; Kelly Bodio; Mark S Huberman; Mark G Kris; Daniel G Tenen; William Pao; Susumu Kobayashi; Daniel B Costa
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):1048-53.
2010: F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; Petra Feyer; S M Grunberg; P J Hesketh; K Jordan; Mark G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 5():v232-43.
2010: Mario Lacouture; Michael L Maitland; Siegfried Segaert; Ann Setser; Robert Baran; Lindy P Fox; Joel B Epstein; Andrei Barasch; Lawrence Einhorn; Lynne Wagner; Dennis P West; Bernardo L Rapoport; Mark G Kris; Ethan Basch; Beth Eaby; Sandra Kurtin; Elise A Olsen; Alice Chen; Janet E Dancey; Andy Trotti
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2010;18(4):509-22.
2010: Yelena Janjigian; Wooin Lee; Mark G Kris; Vincent A Miller; Lee M Krug; Christopher G Azzoli; Emir Senturk; M Wade Calcutt; Naiyer A Rizvi
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Cancer chemotherapy and pharmacology 2010;65(5):833-8.
2010: Yelena Janjigian; Kevin McDonnell; Mark G Kris; Ronglai Shen; Camelia S Sima; Peter B Bach; Naiyer A Rizvi; Gregory J Riely
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.
Cancer 2010;116(3):670-5.
2010: Lin-Chi Chen; Andrew B Brown; Irene Y Cheung; Nai-Kong V Cheung; Mark G Kris; Lee M Krug
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2010;67(2):216-20.
2010: Nicolas Girard; Emil Lou; Christopher G Azzoli; Rekha Reddy; Mark Robson; Megan Harlan; Irene Orlow; Yasushi Yatabe; Khedoudja Nafa; Marc Ladanyi; Agnes Viale; Mark G Kris; Gregory J Riely; Vincent A Miller; Robert J. Klein; Keitaro Matsuo; William Pao
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):755-63.
2010: David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Janne; Thomas Lynch; Bruce E Johnson; Vincent A Miller
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):357-60.
2010: Stephen B Solomon; Maureen F Zakowski; William Pao; Raymond H Thornton; Marc Ladanyi; Mark G Kris; Valerie W Rusch; Naiyer A Rizvi
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
AJR. American journal of roentgenology 2010;194(1):266-9.
2009: Nicholas J Petrelli; Eric P Winer; Julie R Brahmer; Sarita Dubey; Sonali Smith; Charles Thomas; Linda Vahdat; Jennifer Obel; Nicholas Vogelzang; Maurie Markman; John W Sweetenham; David G Pfister; Mark G Kris; Lynn Schuchter; Raymond Sawaya; Derek Raghavan; Patricia Anne Ganz; Barnett Kramer
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(35):6052-69.
2009: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
Journal of the National Cancer Institute 2009;101(23):1624-32.
2009: Barrie R Cassileth; Naiyer A Rizvi; Gary Deng; K Simon Yeung; Andrew J Vickers; Stacey Guillen; Derek Woo; Marci Coleton; Mark G Kris
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
Cancer chemotherapy and pharmacology 2009;65(1):67-71.
2009: Nicolas Girard; Ronglai Shen; Tianhua Guo; Maureen F Zakowski; Adriana Heguy; Gregory J Riely; James Huang; Christopher Lau; Alex E Lash; Marc Ladanyi; Agnes Viale; Cristina R Antonescu; William D Travis; Valerie W Rusch; Mark G Kris; William Pao
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6790-9.
2009: William Pao; Mark G Kris; A John Iafrate; Marc Ladanyi; Pasi A Janne; Ignacio I Wistuba; Ryn Miake-Lye; Roy S Herbst; David P Carbone; Bruce E Johnson; Thomas J Lynch
Integration of molecular profiling into the lung cancer clinic.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5317-22.
2009: Don X Nguyen; Anne C Chiang; Xiang H-F Zhang; Juliet Y Kim; Mark G Kris; Marc Ladanyi; William L Gerald; Joan Massagué
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell 2009;138(1):51-62.
2009: Binsheng Zhao; Leonard P James; Chaya S Moskowitz; Pingzhen Guo; Michelle S Ginsberg; Robert A Lefkowitz; Yilin Qin; Gregory J Riely; Mark G Kris; Lawrence H Schwartz
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.
Radiology 2009;252(1):263-72.
2009: David S Ettinger; Debra K Armstrong; Sally Barbour; Michael J Berger; Philip J Bierman; Bob Bradbury; Georgianna Ellis; Steve Kirkegaard; Dwight D Kloth; Mark G Kris; Dean Lim; Michael Anne Markiewicz; Lida Nabati; Carli Nesheiwat; Hope S Rugo; Steven M Sorscher; Lisa Stucky-Marshal; Barbara Todaro; Susan G Urba
Antiemesis. Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(5):572-95.
2009: Maureen F Zakowski; Sanaa Hussain; William Pao; Marc Ladanyi; Michelle S Ginsberg; Robert T Heelan; Vincent A Miller; Valerie W Rusch; Mark G Kris
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Archives of pathology & laboratory medicine 2009;133(3):470-7.
2009: Eric Winer; Julie Gralow; Lisa Diller; Beth Y Karlan; Patrick Loehrer; Lori J Pierce; George Demetri; Patricia Anne Ganz; Barnett Kramer; Mark G Kris; Maurie Markman; Robert Mayer; David G Pfister; Derek Raghavan; Scott Ramsey; Gregory Reaman; Howard Sandler; Raymond Sawaya; Lynn Schuchter; John Sweetenham; Linda Vahdat; Richard L Schilsky
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):812-26.
2009: Ilya Glezerman; Mark G Kris; Vincent A Miller; Surya V Seshan; Carlos D Flombaum
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
Clinical nephrology 2009;71(2):130-9.
2009: Gregory J Riely; Naiyer A Rizvi; Mark G Kris; Daniel T Milton; David B Solit; Neal Rosen; Emir Senturk; Christopher G Azzoli; Julie R Brahmer; Francis M Sirotnak; Venkatraman E Seshan; Margaret Fogle; Michelle Ginsberg; Vincent A Miller; Charles Rudin
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):264-70.
2008: Gregory J Riely; Mark G Kris; Daniel Rosenbaum; Jenifer Marks; Allan Li; Dhananjay A Chitale; Khedoudja Nafa; Elyn Riedel; Meier Hsu; William Pao; Vincent A Miller; Marc Ladanyi
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5731-4.
2008: Kerby Shedden; Jeremy Taylor; Steven A Enkemann; Ming Tsao; Timothy J Yeatman; William L Gerald; Steven Eschrich; Igor Jurisica; Thomas J Giordano; David E Misek; Andrew C Chang; Chang-Qi Zhu; Daniel Strumpf; Samir Hanash; Frances A Shepherd; Keyue Ding; Lesley Seymour; Katsuhiko Naoki; Nathan Pennell; Barbara Weir; Roel Verhaak; Christine Ladd-Acosta; Todd Golub; Michael Gruidl; Anupama Sharma; Janos Szoke; Maureen Zakowski; Valerie W Rusch; Mark G Kris; Agnes Viale; Noriko Motoi; William D Travis; BA Conley; Venkatraman E Seshan; Matthew Meyerson; Rork Kuick; Kevin K Dobbin; Tracy Lively; James W Jacobson; David G Beer
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Nature medicine 2008;14(8):822-7.
2008: Irene Orlow; Bernard J Park; Urvi Mujumdar; Himali Patel; Puiki Siu-Lau; Brian A Clas; Robert J Downey; Raja M Flores; Manjit S Bains; Nabil P Rizk; Gemma Dominguez; Jen Jani; Marianne Berwick; Colin B Begg; Mark G Kris; Valerie W Rusch
DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3560-6.
2008: Mark G Kris
Foreword; challenging the 'one-size-fits-all' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2008;60 Suppl 2():S1-2.
2008: Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
The American journal of surgical pathology 2008;32(6):810-27.
2008: Allan R Li; Dhananjay Chitale; Gregory J Riely; William Pao; Vincent A Miller; Maureen F Zakowski; Valerie W Rusch; Mark G Kris; Marc Ladanyi
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
The Journal of molecular diagnostics : JMD 2008;10(3):242-8.
2008: Vincent A Miller; Gregory J Riely; Maureen F Zakowski; Allan R Li; Jyoti D Patel; Robert T Heelan; Mark G Kris; Alan B Sandler; David P Carbone; Anne Tsao; Roy S Herbst; Glenn Heller; Marc Ladanyi; William Pao; David H Johnson
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1472-8.
2008: David S Ettinger; Wallace Akerley; Gerold Bepler; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Steven Feigenberg; Robert A Figlin; Ramaswamy Govindan; Frederic W Grannis; Thierry jahan; Mohammad Jahanzeb; Anne Kessinger; Ritsuko Komaki; Mark G Kris; Corey J Langer; Quynh-Thu Le; Renato Martins; Gregory A Otterson; Jyoti D Patel; Francisco Robert; David J Sugarbaker; Douglas E Wood
Non-small cell lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(3):228-69.
2008: Jenifer L Marks; Stephen Broderick; Qin Zhou; Dhananjay Chitale; Allan R Li; Maureen F Zakowski; Mark G Kris; Valerie W Rusch; Christopher G Azzoli; Venkatraman E Seshan; Marc Ladanyi; William Pao
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):111-6.
2008: Naiyer A Rizvi; Gregory J Riely; Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; John Fiore; Gloria Chia; Martin Brower; Robert T Heelan; Michael J Hawkins; Mark G Kris
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):639-43.
2008: Julie R Gralow; Robert F Ozols; Dean F Bajorin; Bruce D Cheson; Howard M Sandler; Eric P Winer; James Bonner; George D Demetri; Walter Curran; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Scott Ramsey; Gregory H Reaman; Raymond Sawaya; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Nancy E Davidson; Richard L Schilsky; Allen S Lichter
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):313-25.
2008: Christopher G Azzoli; Bernard J Park; William Pao; Maureen F Zakowski; Mark G Kris
Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(1):84-93.
2008: Inderpal S Sarkaria; Maureen F Zakowski; Duykhanh Pham; Michael Hezel; Michael I Ebright; Shaokun Chuai; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; Bhuvanesh Singh
Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
The Annals of thoracic surgery 2008;85(1):216-23.
2007: Barbara A Weir; Michele S Woo; Gad Getz; Sven Perner; Li Ding; Rameen Beroukhim; William M Lin; Michael A Province; Aldi Kraja; Laura A Johnson; Kinjal Shah; Mitsuo Sato; Roman K Thomas; Justine A Barletta; Ingrid B Borecki; Stephen Broderick; Andrew C Chang; Derek Chiang; Lucian R Chirieac; Jeonghee Cho; Yoshitaka Fujii; Adi F Gazdar; Thomas J Giordano; Heidi Greulich; Megan Hanna; Bruce E Johnson; Mark G Kris; Alex E Lash; Ling Lin; Neal Lindeman; Elaine R Mardis; John D McPherson; John D Minna; Margaret B Morgan; Mark Nadel; Mark B Orringer; John R Osborne; Brad Ozenberger; Alex H Ramos; James Robinson; Jack A Roth; Valerie W Rusch; Hidefumi Sasaki; Frances Shepherd; Carrie Sougnez; Margaret R Spitz; Ming Tsao; David Twomey; Roel G W Verhaak; George Weinstock; David A Wheeler; Wendy Winckler; Akihiko Yoshizawa; Soyoung Yu; Maureen F Zakowski; Qunyuan Zhang; David G Beer; Ignacio I Wistuba; Mark A Watson; Levi A Garraway; Marc Ladanyi; William D Travis; William Pao; Mark A Rubin; Stacey B Gabriel; Richard A Gibbs; Harold Varmus; Richard K Wilson; Eric S Lander; Matthew Meyerson
Characterizing the cancer genome in lung adenocarcinoma.
Nature 2007;450(7171):893-8.
2007: Ethan Basch; Alexia Iasonos; Allison Barz; Ann Culkin; Mark G Kris; David Artz; Paul Fearn; John Speakman; Rena Farquhar; Howard I Scher; Mary McCabe; Deborah Schrag
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5374-80.
2007: Katherine M W Pisters; William K Evans; Christopher G Azzoli; Mark G Kris; Christopher A Smith; Christopher E Desch; Mark R Somerfield; Melissa Brouwers; Gail Darling; Peter M Ellis; Laurie E Gaspar; Harvey I Pass; David R Spigel; John R Strawn; Yee C Ung; Frances A Shepherd
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5506-18.
2007: Lee M Krug; Daniel T Milton; Achim A Jungbluth; Lin-Chi Chen; Emilio Quaia; Neeta Pandit-Taskar; Andrew Nagel; Jessica Jones; Mark G Kris; Ronald Finn; Peter Smith-Jones; Andrew M Scott; Lloyd J Old; Chaitanya R Divgi
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(10):947-52.
2007: Vincent Liu; Dorothy A White; Maureen F Zakowski; William D Travis; Mark G Kris; Michelle S Ginsberg; Vincent A Miller; Christopher G Azzoli
Pulmonary toxicity associated with erlotinib.
Chest 2007;132(3):1042-4.
2007: Gregory J Riely; Mark G Kris; Binsheng Zhao; Timothy Akhurst; Daniel T Milton; Erin Moore; Leslie Tyson; William Pao; Naiyer A Rizvi; Lawrence H Schwartz; Vincent A Miller
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5150-5.
2007: Daniel T Milton; Gregory J Riely; Christopher G Azzoli; Jorge Gomez; Robert T Heelan; Mark G Kris; Lee M Krug; William Pao; Barbara Pizzo; Naiyer A Rizvi; Vincent A Miller
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Cancer 2007;110(3):599-605.
2007: Christopher G Azzoli; Lee M Krug; Vincent A Miller; Naiyer A Rizvi; Mark G Kris; Megan Dunne; Amy Farmer; Barbara Pizzo; Leslie Tyson; Teresa Seeger; Barbara Coleman; Erin Moore; Lauren Lastinger; Venkatraman E Seshan; Charles Rudin
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(7):638-44.
2007: Christopher G Azzoli; Mark G Kris; David G Pfister
Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed.
Journal of the National Cancer Institute 2007;99(11):828-9.
2007: Christopher G Azzoli; Lee M Krug; Jorge Gomez; Vincent A Miller; Mark G Kris; Michelle S Ginsberg; Roxanne Henry; Jessica Jones; Leslie Tyson; Megan Dunne; Barbara Pizzo; Amy Farmer; Venkatraman E Seshan; Robert Steffen; Francis M Sirotnak
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2692-8.
2007: Lee M Krug; Robert T Heelan; Mark G Kris; Venkatraman E Seshan; Francis M Sirotnak
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(4):317-20.
2007: Matthew G Fury; David B Solit; Yungpo Bernard Su; Neal Rosen; Francis M Sirotnak; Robert P Smith; Christopher G Azzoli; Jorge Gomez; Vincent A Miller; Mark G Kris; Barbara A Pizzo; Roxanne Henry; David G Pfister; Naiyer A Rizvi
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2007;59(4):467-75.
2007: Gregory A Otterson; Miguel A Villalona-Calero; Sunil Sharma; Mark G Kris; Anthony Imondi; Mirjam Gerber; Dorothy A White; Mark J Ratain; Joan H Schiller; Alan B Sandler; Michael Kraut; Sridhar Mani; John R Murren
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1246-52.
2007: Gregory J Riely; Shirish M Gadgeel; Ivan Rothman; Bruce Saidman; Kert Sabbath; Kevie Feit; Mark G Kris; Naiyer A Rizvi
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2007;55(2):181-5.
2007: Jenifer L Marks; Michael D McLellan; Maureen F Zakowski; Alex E Lash; Yumi Kasai; Stephen Broderick; Inderpal S Sarkaria; Duykhanh Pham; Bhuvanesh Singh; Tracie L Miner; Ginger A Fewell; Lucinda L Fulton; Elaine R Mardis; Richard K Wilson; Mark G Kris; Valerie W Rusch; Harold Varmus; William Pao
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
PloS one 2007;2(5):e426.
2007: David S Ettinger; Philip J Bierman; Bob Bradbury; Carli C Comish; Georgiana Ellis; Robert J Ignoffo; Steve Kirkegaard; Dwight D Kloth; Mark G Kris; Dean Lim; Michael Anne Markiewicz; Robert McNulty; Lidia Nabati; Barbara Todaro; Susan G Urba; Sally Yowell
Antiemesis.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(1):12-33.
2007: Robert F Ozols; Roy S Herbst; Yolonda L Colson; Julie R Gralow; James Bonner; Walter Curran; Burton L Eisenberg; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Richard L Schilsky; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Rodger J Winn
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):146-62.
2006: Binsheng Zhao; Lawrence H Schwartz; Chaya S Moskowitz; Michelle S Ginsberg; Naiyer A Rizvi; Mark G Kris
Lung cancer: computerized quantification of tumor response--initial results.
Radiology 2006;241(3):892-8.
2006: Mark G Kris; Giuseppe Giaccone; Angela Davies; Masahiro Fukuoka; David H Garfield; Jacek Jassem; Elisabeth Quoix; Alan B Sandler; Giorgio V Scagliotti; Jan P van Meerbeeck; Howard West
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9 Suppl):S32-6.
2006: Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6494-501.
2006: Ethan Basch; Alexia Iasonos; Tiffani McDonough; Allison Barz; Ann Culkin; Mark G Kris; Howard I Scher; Deborah Schrag
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
The lancet oncology 2006;7(11):903-9.
2006: Daniel T Milton; Gregory J Riely; William Pao; Vincent A Miller; Mark G Kris; Robert T Heelan
Molecular on/off switch.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4940-2.
2006: Arti Hurria; Mark T Fleming; Sharyn D Baker; W Kevin Kelly; Katie Cutchall; Katherine S Panageas; James Caravelli; Henry Yeung; Mark G Kris; Jorge Gomez; Vincent A Miller; Gabriella D'Andrea-Carlino; Howard I Scher; Larry Norton; Clifford Hudis
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
2006: Daniel T Milton; Christopher G Azzoli; Robert T Heelan; Venkatraman E Seshan; Jorge Gomez; Mark G Kris; Lee M Krug; William Pao; Naiyer A Rizvi; Megan Dunne; Vincent A Miller
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Cancer 2006;107(5):1034-41.
2006: Maureen F Zakowski; Marc Ladanyi; Mark G Kris
EGFR mutations in small-cell lung cancers in patients who have never smoked.
The New England journal of medicine 2006;355(2):213-5.
2006: David S Ettinger; Gerold Bepler; Raphael Bueno; Andrew C Chang; Joe Y Chang; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Steven Feigenberg; Frederic W Grannis; Thierry jahan; Mohammad Jahanzeb; Anne Kessinger; Ritsuko Komaki; Mark G Kris; Corey J Langer; Quynh-Thu Le; Renato Martins; Gregory A Otterson; Francisco Robert; David J Sugarbaker; Douglas E Wood
Non-small cell lung cancer clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(6):548-82.
2006: Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca A Clark-Snow; Jim M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2932-47.
2006: Matthew G Fury; Lee M Krug; Christopher G Azzoli; Sunil Sharma; Nancy Kemeny; Nian Wu; Mark G Kris; Naiyer A Rizvi
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Cancer chemotherapy and pharmacology 2006;57(5):671-7.
2006: Duykhanh Pham; Mark G Kris; Gregory J Riely; Inderpal S Sarkaria; Tiffani McDonough; Shaokun Chuai; Venkatraman E Seshan; Vincent A Miller; Marc Ladanyi; William Pao; Richard K Wilson; Bhuvanesh Singh; Valerie W Rusch
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1700-4.
2006: Natalie Moryl; Eugenie A Obbens; Obinna Henry Ozigbo; Mark G Kris
Analgesic effect of gefitinib in the treatment of non-small cell lung cancer.
The journal of supportive oncology 2006;4(3):111.
2006: Gregory J Riely; William Pao; Duykhanh Pham; Allan R Li; Naiyer A Rizvi; Venkatraman E Seshan; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Vincent A Miller
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):839-44.
2006: Roy S Herbst; Dean F Bajorin; Harry Bleiberg; Diane Blum; Desirée Hao; Bruce E Johnson; Robert F Ozols; George D Demetri; Patricia Anne Ganz; Mark G Kris; Bernard Levin; Maurie Markman; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Everett E Vokes; Rodger J Winn; Robert J Mayer
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):190-205.
2005: Lee M Krug; Vincent A Miller; Jyoti Patel; John P Crapanzano; Christopher G Azzoli; Jorge Gomez; Mark G Kris; Robert T Heelan; Barbara Pizzo; Leslie Tyson; Christine Sheehan; Jeffrey S Ross; Venkatraman E Seshan
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Cancer 2005;104(10):2149-55.
2005: Mark G Kris
New approaches in the management of lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3 Suppl 1():S22-4.
2005: Arti Hurria; Supriya Gupta; Marjorie Zauderer; Enid Zuckerman; Harvey J Cohen; Hyman Muss; Miriam Rodin; Katherine S Panageas; Jimmie C Holland; Leonard B Saltz; Mark G Kris; Ariela Noy; Jorge Gomez; Ann Jakubowski; Clifford Hudis; Alice B Kornblith
Developing a cancer-specific geriatric assessment: a feasibility study.
Cancer 2005;104(9):1998-2005.
2005: Daphne W Bell; Thomas J Lynch; Sara M Haserlat; Patricia Neal; Ross A Okimoto; Brian W Brannigan; Dennis C Sgroi; Beth Muir; Markus J Riemenschneider; Renee Bailey Iacona; Annetta D Krebs; David H Johnson; Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Masahiro Fukuoka; Mark G Kris; José Baselga; Judith S Ochs; Daniel A Haber
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8081-92.
2005: Mark G Kris
How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
The oncologist 2005;10 Suppl 2():23-9.
2005: Philip O Livingston; Chandra Hood; Lee M Krug; N Warren; Mark G Kris; T Brezicka; Govind Ragupathi
Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Cancer immunology, immunotherapy : CII 2005;54(10):1018-25.
2005: Roy S Herbst; Diane Prager; Robert Hermann; Louis Fehrenbacher; Bruce E Johnson; Alan B Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David A Ramies; David H Johnson; Vincent A Miller
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5892-9.
2005: Antonio M P Omuro; Mark G Kris; Vincent A Miller; Enrico Franceschi; Neelam Shah; Daniel T Milton; Lauren E Abrey
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Cancer 2005;103(11):2344-8.
2005: Kenneth E Rosenzweig; Jana L Fox; Ellen Yorke; Howard Amols; Andrew Jackson; Valerie W Rusch; Mark G Kris; C Clifton Ling; Steven A Leibel
Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
Cancer 2005;103(10):2118-27.
2005: Lee M Krug; John P Crapanzano; Christopher G Azzoli; Vincent A Miller; Naiyer A Rizvi; Jorge Gomez; Mark G Kris; Barbara Pizzo; Leslie Tyson; Megan Dunne; Robert T Heelan
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Cancer 2005;103(10):2128-31.
2005: David Cella; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Anne Heyes; Judith S Ochs; Michael K Wolf; Andrea C Kay; Mark G Kris; Ronald B Natale
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2946-54.
2005: Patricia J Hollen; Richard J Gralla; Mark G Kris; S McCoy; Gary W Donaldson; Carol M Moinpour
A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life?
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2005;14(3):837-47.
2005: David B Solit; Yuhong She; Jose Lobo; Mark G Kris; Howard I Scher; Neal Rosen; Francis M Sirotnak
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1983-9.
2005: William Pao; Vincent A Miller; Katerina Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PLoS medicine 2005;2(3):e73.
2005: Mark G Kris; Paul J Hesketh; Jørn Herrstedt; Cynthia N Rittenberg; Lawrence H Einhorn; Steven M Grunberg; Jim M Koeller; Ian Olver; Sussanne Borjeson; Enzo Ballatori
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(2):85-96.
2005: William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold Varmus
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PLoS medicine 2005;2(1):e17.
2005: Daniel T Milton; Mark G Kris; Jorge Gomez; Marc B Feinstein
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(1):70-2.
2005: Neelam T Shah; Mark G Kris; William Pao; Leslie Tyson; Barbara Pizzo; Murk-Hein Heinemann; Leah Ben-Porat; Dana L Sachs; Robert T Heelan; Vincent A Miller
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):165-74.
2005: Scott A Laurie; Vincent A Miller; Stefan C Grant; Mark G Kris; Kenneth K Ng
Phase I study of green tea extract in patients with advanced lung cancer.
Cancer chemotherapy and pharmacology 2005;55(1):33-8.
2004: Inderpal S Sarkaria; Duykhanh Pham; Ronald A Ghossein; Simon G Talbot; Michael Hezel; Maria E Dudas; Michael I Ebright; Shaokun Chuai; Natalie Memoli; Venkatraman E Seshan; Vincent A Miller; Mark G Kris; Maureen F Zakowski; Valerie W Rusch; Bhuvanesh Singh
SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2004;78(5):1734-41.
2004: Lee M Krug; Govind Ragupathi; Chandra Hood; Mark G Kris; Vincent A Miller; Jennifer R Allen; Stacy J Keding; Samuel J Danishefsky; Jorge Gomez; Leslie Tyson; Barbara Pizzo; Valerie Baez; Philip O Livingston
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6094-100.
2004: William Pao; Vincent A Miller; Maureen F Zakowski; Jennifer Doherty; Katerina Politi; Inderpal S Sarkaria; Bhuvanesh Singh; Robert T Heelan; Valerie W Rusch; Lucinda Fulton; Elaine R Mardis; Doris Kupfer; Richard Wilson; Mark G Kris; Harold Varmus
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(36):13306-11.
2004: David S Ettinger; Philip J Bierman; Bob Bradbury; Georgiana Ellis; Robert J Ignoffo; Steve Kirkegaard; Dwight Kloth; Amy Krauss; Mark G Kris; Dean Lim; Michael Anne Markiewicz; Robert McNulty; Kim Noonan; Lisa Stucky-Marshall; Barbara Todaro; Susan G Urba; Sally Yowell
Antiemesis clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(5):470-90.
2004: William Pao; Vincent A Miller; Venkatraman E Seshan; Mark G Kris
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
Journal of the National Cancer Institute 2004;96(15):1117-9.
2004: Simon G Talbot; Pornchai O-Charoenrat; Inderpal S Sarkaria; Ronald A Ghossein; Pabbathi Reddy; Ivan Ngai; Christina N Cordeiro; Richard J Wong; Mark G Kris; Valerie W Rusch; Bhuvanesh Singh
Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A.
Annals of surgical oncology 2004;11(5):530-4.
2004: Jyoti D Patel; Peter B Bach; Mark G Kris
Lung cancer in US women: a contemporary epidemic.
JAMA : the journal of the American Medical Association 2004;291(14):1763-8.
2004: Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher G Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer A Rizvi; Barbara Pizzo; Leslie Tyson; Venkatraman E Seshan; Leah Ben-Porat; Natalie Memoli; Maureen F Zakowski; Valerie W Rusch; Robert T Heelan
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1103-9.
2004: Lee M Krug; Govind Ragupathi; Kenneth K Ng; Chandra Hood; Harold J Jennings; Zhongwu Guo; Mark G Kris; Vincent A Miller; Barbara Pizzo; Leslie Tyson; Valerie Baez; Philip O Livingston
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):916-23.
2004: William Pao; Vincent A Miller; Mark G Kris
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Seminars in cancer biology 2004;14(1):33-40.
2003: Mark G Kris
Why do we need another antiemetic? Just ask.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(22):4077-80.
2003: Arti Hurria; Mark G Kris
Management of lung cancer in older adults.
CA: a cancer journal for clinicians 2003;53(6):325-41.
2003: Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan B Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
JAMA : the journal of the American Medical Association 2003;290(16):2149-58.
2003: Yuhong She; Fei Lee; Jing Chen; Adriana Haimovitz-Friedman; Vincent A Miller; Valerie R Rusch; Mark G Kris; Francis M Sirotnak
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3773-8.
2003: Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; Lee M Krug; Martee Hensley; Eileen O'Reilly; Raymond J Muller; Mark G Kris
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.
American journal of clinical oncology 2003;26(3):247-51.
2003: Lee M Krug; Christopher G Azzoli; Mark G Kris; Vincent A Miller; Nushmia Z Khokhar; William Tong; Michelle S Ginsberg; Venkatraman E Seshan; Leslie Tyson; Barbara Pizzo; Valerie Baez; Kenneth K Ng; Francis M Sirotnak
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2072-8.
2003: Vincent A Miller; David H Johnson; Lee M Krug; Barbara Pizzo; Leslie Tyson; Wendy Perez; Peggy Krozely; Alan B Sandler; David Carbone; Robert T Heelan; Mark G Kris; Robert Smith; Judith Ochs
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2094-100.
2003: Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; Lee M Krug; David Spriggs; William P Tong; Elyn Riedel; Mark G Kris
A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2003;51(6):493-8.
2003: Peter B Bach; Michael W Kattan; Mark D Thornquist; Mark G Kris; Ramsey C Tate; Matt J Barnett; Lillian J Hsieh; Colin B Begg
Variations in lung cancer risk among smokers.
Journal of the National Cancer Institute 2003;95(6):470-8.
2003: Jyoti D Patel; Lee M Krug; Christopher G Azzoli; Jorge Gomez; Mark G Kris; Vincent A Miller
Targeting lethal minimal residual disease in small cell lung cancer.
Seminars in oncology 2003;30(1):79-85.
2003: Lee M Krug; Vincent A Miller; Daniel A Filippa; Venkatraman E Seshan; Kenneth K Ng; Mark G Kris
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Lung cancer (Amsterdam, Netherlands) 2003;39(2):139-43.
2002: Mark G Kris; Maurizio Tonato
New approaches in the treatment of non-small cell lung cancer: taxanes in the treatment of NSCLC: pathways to progress.
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 4():1-3.
2002: Michael I Ebright; Maureen F Zakowski; Jocelyne Martin; Venkatraman E Seshan; Vincent A Miller; Manjit S Bains; Robert J Downey; Robert J Korst; Mark G Kris; Valerie W Rusch
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2002;74(5):1640-6; discussion 1646-7.
2002: Robert J Downey; Kenneth K Ng; Mark G Kris; Manjit S Bains; Vincent A Miller; Robert T Heelan; Mark H Bilsky; Robert J Ginsberg; Valerie W Rusch
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.
Lung cancer (Amsterdam, Netherlands) 2002;38(2):193-7.
2002: Jim M Koeller; Matti S Aapro; Richard J Gralla; Steven M Grunberg; Paul J Hesketh; Mark G Kris; Rebecca A Clark-Snow
Antiemetic guidelines: creating a more practical treatment approach.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2002;10(7):519-22.
2002: Scott A Laurie; Mark G Kris; Carol S Portlock; Kenneth E Rosenzweig; Vincent A Miller; Lee M Krug; Valerie W Rusch
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.
Cancer 2002;95(1):119-26.
2002: Gabriel N Hortobagyi; Mark G Kris
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Seminars in oncology 2002;29(3 Suppl 12):1-3.
2002: Malcolm Ranson; Lisa A Hammond; David Ferry; Mark G Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steven D Averbuch; Judith S Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2240-50.
2002: Jocelyne Martin; Robert J Ginsberg; Venkatraman E Seshan; Manjit S Bains; Robert J Downey; Robert J Korst; Mark G Kris; Valerie W Rusch
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):1989-95.
2002: Christopher G Azzoli; Lee M Krug; Vincent A Miller; Mark G Kris; Robert Mass
Trastuzumab in the treatment of non-small cell lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):59-65.
2001: Mark G Kris; Christopher G Azzoli
Chemotherapy for early stage non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S49-52.
2001: David S Ettinger; Mark G Kris
NCCN: Non-small cell lung cancer.
Cancer control : journal of the Moffitt Cancer Center 2001;8(6 Suppl 2):22-31.
2001: Jocelyne Martin; Robert J Ginsberg; A Abolhoda; Manjit S Bains; Robert J Downey; Robert J Korst; Tracey L Weigel; Mark G Kris; Venkatraman E Seshan; Valerie W Rusch
Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy.
The Annals of thoracic surgery 2001;72(4):1149-54.
2001: M Kawahara; Mark G Kris; M Green; H Kunitoh
New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer.
Seminars in oncology 2001;28(3 Suppl 9):1-4.
2001: S Sharma; D White; AR Imondi; ME Placke; David M Vail; Mark G Kris
Development of inhalational agents for oncologic use.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1839-47.
2001: Scott A Laurie; David G Pfister; Mark G Kris; William P Tong; Gregory M Chronowski; Katherine M W Pisters; Robert T Heelan; Francis M Sirotnak
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):501-9.
2001: Frances A Shepherd; F V Fossella; Thomas J Lynch; J P Armand; James R Rigas; Mark G Kris
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Seminars in oncology 2001;28(1 Suppl 2):4-9.
2001: Mark G Kris; C Manegold
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.
Seminars in oncology 2001;28(1 Suppl 2):1-3.
2000: Francis M Sirotnak; Maureen F Zakowski; Vincent A Miller; Howard I Scher; Mark G Kris
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4885-92.
2000: Francis M Sirotnak; Hans-Guido Wendel; William G Bornmann; William P Tong; Vincent A Miller; Howard I Scher; Mark G Kris
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3705-12.
2000: Lee M Krug; Kenneth K Ng; Mark G Kris; Vincent A Miller; William Tong; Robert T Heelan; L Leon; D Leung; J Kelly; Stefan C Grant; Francis M Sirotnak
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3493-8.
2000: Frank V Fossella; Russell F DeVore; R N Kerr; Jeffrey Crawford; R R Natale; F Dunphy; L Kalman; Vincent A Miller; Jin S Lee; M Moore; David R Gandara; D Karp; Everett E Vokes; Mark G Kris; Y Kim; F Gamza; Luz D Hammershaimb
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2354-62.
2000: Scott A Laurie; Mark G Kris
Single-agent docetaxel (Taxotere) in the treatment of advanced non small-cell lung cancer: clinical concepts and commentary.
Clinical lung cancer 2000;1 Suppl 1():S5-9.
2000: Vincent A Miller; Mark G Kris
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Seminars in oncology 2000;27(2 Suppl 3):3-10.
2000: Kenneth E Rosenzweig; Borys Mychalczak; Zvi Fuks; Joseph Hanley; Chandra M Burman; C Clifton Ling; J Armstrong; Robert J Ginsberg; Mark G Kris; Adam Raben; Steven Leibel
Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
Cancer journal (Sudbury, Mass.) 2000;6(2):82-7.
2000: Vincent A Miller; Lee M Krug; Kenneth K Ng; Barbara Pizzo; Wendy Perez; Robert T Heelan; Mark G Kris
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1346-50.
2000: Vincent A Miller; Kenneth K Ng; Lee M Krug; Wendy Perez; Barbara Pizzo; Robert T Heelan; Mark G Kris
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Cancer 2000;88(5):1045-50.
2000: Katherine M W Pisters; R J Ginsberg; Dorothy J Giroux; Joe B Putnam; Mark G Kris; D H Johnson; J R Roberts; J Mault; John J Crowley; P A Bunn
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.
The Journal of thoracic and cardiovascular surgery 2000;119(3):429-39.
2000: Lee M Krug; Vincent A Miller; Gregory P Kalemkerian; M J Kraut; Kenneth K Ng; Robert T Heelan; Barbara A Pizzo; Wendy Perez; N McClean; Mark G Kris
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):227-8.
1999: KR Parekh; Valerie W Rusch; Mark G Kris
The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.
Cancer 1999;86(9):1720-3.
1999: Lee M Krug; Stefan C Grant; Vincent A Miller; Kenneth K Ng; Mark G Kris
Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination.
Seminars in oncology 1999;26(5 Suppl 15):55-61.
1999: Maura Dickler; Govind Ragupathi; Nancy X Liu; Cristina Musselli; D J Martino; Vincent A Miller; Mark G Kris; F T Brezicka; Philip O Livingston; Stefan C Grant
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2773-9.
1999: Kenneth K Ng; Mark G Kris; Robert J Ginsberg; Robert T Heelan; Katherine M W Pisters; Vincent A Miller; Stefan C Grant; Manjit S Bains; Valerie W Rusch; Kenneth E Rosenzweig; N Martini
Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.
Cancer 1999;86(7):1189-97.
1999: Richard J Gralla; David Osoba; Mark G Kris; P Kirkbride; Paul J Hesketh; L W Chinnery; Rebecca A Clark-Snow; D P Gill; S Groshen; Steven M Grunberg; Jim M Koeller; Gary R Morrow; Edith A Perez; J H Silber; David G Pfister
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2971-94.
1999: Mark G Kris; M Millward
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Seminars in oncology 1999;26(3 Suppl 10):1-2.
1999: Stefan C Grant; Mark G Kris; Alan N Houghton; Paul B Chapman
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1319-23.
1999: JR Rigas; Mark G Kris; Vincent A Miller; Katherine M W Pisters; Robert T Heelan; Stefan C Grant; DW Fennelly; T C Chou; Francis M Sirotnak
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):601-3.
1999: Patricia J Hollen; Richard J Gralla; Mark G Kris; S W Eberly; C Cox
Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(3):140-8.
1999: Rudolph M Navari; Rick R Reinhardt; Richard J Gralla; Mark G Kris; Paul J Hesketh; A Khojasteh; H Kindler; Tobias Grote; Kelly Pendergrass; Steven M Grunberg; Alexandra D Carides; Barry J Gertz
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
The New England journal of medicine 1999;340(3):190-5.
1999: Barbara A Pizzo; Katherine M W Pisters; Vincent A Miller; Stefan C Grant; L Baltzer; L Hinckley; Mark G Kris
Oral cisapride for the control of delayed vomiting following high-dose cisplatin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(1):44-6.
1999: N Martini; Valerie W Rusch; Manjit S Bains; Mark G Kris; Robert J Downey; B J Flehinger; Robert J Ginsberg
Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer.
The Journal of thoracic and cardiovascular surgery 1999;117(1):32-6; discussion 37-8.
1998: Hedy L Kindler; Mark G Kris; I E Smith; Vincent A Miller; Stefan C Grant; J B Krebs; G A Ross; M L Slevin
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
American journal of clinical oncology 1998;21(5):438-41.
1998: George D Demetri; Mark G Kris; James L Wade Iii; L Degos; David Cella
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3412-25.
1998: J B Whitmore; Mark G Kris; Paul J Hesketh; Tobias Grote; D M DuBois; MB Cramer; WF Hahne
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(5):473-8.
1998: Mark G Kris
What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer?
Seminars in oncology 1998;25(3 Suppl 8):1-4.
1998: P H De Mulder; Fausto Roila; Mark G Kris; M M Marty
Consensus regarding multiple day and rescue antiemetic therapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(3):248-52.
1998: Mark G Kris; Fausto Roila; P H De Mulder; Michel Marty
Delayed emesis following anticancer chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(3):228-32.
1998: M J Nolte; R Berkery; Barbara Pizzo; L Baltzer; D Grossano; Charles D Lucarelli; Mark G Kris
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):771-8.
1997: Vincent A Miller; Kenneth K Ng; Stefan C Grant; Hedy L Kindler; Barbara Pizzo; Robert T Heelan; R von Roemeling; Mark G Kris
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1269-71.
1997: Patricia J Hollen; Richard J Gralla; C Cox; S W Eberly; Mark G Kris
A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer.
Lung cancer (Amsterdam, Netherlands) 1997;18(2):119-36.
1997: N Martini; Mark G Kris; Robert J Ginsberg
The role of multimodality therapy in locoregional non-small cell lung cancer.
Surgical oncology clinics of North America 1997;6(4):769-91.
1997: Mark G Kris
Lung cancer cure, care, and cost: let the data be your guide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(9):3027-9.
1997: Mark G Kris; Vincent A Miller; Kenneth K Ng; Stefan C Grant
The development of docetaxel (Taxotere) in non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 14):S14-1-S14-4.
1997: Katherine M W Pisters; Mark G Kris; P A Bunn; D H Johnson; John Ruckdeschel; John J Crowley; R J Ginsberg
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.
Seminars in oncology 1997;24(4 Suppl 12):S12-41-S12-44.
1997: J Armstrong; Adam Raben; Michael J Zelefsky; M Burt; Steven Leibel; Chandra M Burman; Gerald J Kutcher; Louis B Harrison; C Hahn; Robert J Ginsberg; Valerie W Rusch; Mark G Kris; Zvi Fuks
Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1997;44(1):17-22.
1997: Enzo Ballatori; Fausto Roila; Verena de Angelis; G Ciccarese; MA Palladino; Maurizio Tonato; Albano Del Favero; Jørn Herrstedt; Mario Dicato; Andreas du Bois; Paul J Hesketh; Mark G Kris; Richard J Gralla
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(4):269-73.
1997: Mark G Kris; J E Radford; B A Pizzo; R Inabinet; Ann M Hesketh; P J Hesketh
Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.
Journal of the National Cancer Institute 1997;89(11):817-8.
1997: Mark G Kris; Kelly Pendergrass; Rudolph M Navari; Tobias Grote; A M Nelson; V Thomas; B B Ferguson; D S Allman; Barbara A Pizzo; T W Baker; I J Fernando; S B Chernoff
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):2135-8.
1997: Vincent A Miller; FM Benedetti; JR Rigas; A L Verret; David G Pfister; David J Straus; Mark G Kris; M Crisp; R Heyman; GR Loewen; JA Truglia; RP Warrell
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):790-5.
1997: Vincent A Miller; JR Rigas; William P Tong; J R Reid; Katherine M W Pisters; Stefan C Grant; Robert T Heelan; Mark G Kris
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(5):415-8.
1997: Paul J Hesketh; Mark G Kris; Steven M Grunberg; T Beck; J D Hainsworth; G Harker; Matti S Aapro; David R Gandara; C M Lindley
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):103-9.
1996: Mark G Kris; L X Cubeddu; R J Gralla; D Cupissol; L B Tyson; Venkatraman E Seshan; Howard D Homesley
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.
Cancer 1996;78(10):2193-8.
1996: Katherine M W Pisters; L B Tyson; William Tong; Martin Fleisher; Vincent A Miller; Stefan C Grant; David G Pfister; J R Rigas; C L Densmore; G Krol; Robert T Heelan; Francis M Sirotnak; Joseph R Bertino; Mark G Kris
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(11):1819-24.
1996: David S Ettinger; J D Cox; R J Ginsberg; R Komaki; Mark G Kris; R B Livingston; D J Sugarbaker
NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.
Oncology (Williston Park, N.Y.) 1996;10(11 Suppl):81-111.
1996: Paul J Hesketh; Rudolph M Navari; Tobias Grote; Richard J Gralla; J Hainsworth; Mark G Kris; L Anthony; A Khojasteh; E Tapazoglou; C Benedict; W Hahne
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2242-9.
1996: J R Rigas; Vincent A Miller; Zuo-Feng Zhang; David S Klimstra; William P Tong; Mark G Kris; RP Warrell
Metabolic phenotypes of retinoic acid and the risk of lung cancer.
Cancer research 1996;56(12):2692-6.
1996: Vincent A Miller; J R Rigas; F M Benedetti; A L Verret; William P Tong; Mark G Kris; G M Gill; GR Loewen; JA Truglia; E H Ulm; RP Warrell
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):471-5.
1996: Stefan C Grant; L Kostakoglu; Mark G Kris; Samuel D J Yeh; Steven M Larson; Ronald D Finn; H F Oettgen; Nai-Kong V Cheung
Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial.
European journal of nuclear medicine 1996;23(2):145-9.
1995: Valerie W Rusch; David S Klimstra; Venkatraman E Seshan; J Oliver; N Martini; R Gralla; Mark G Kris; Ethan Dmitrovsky
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
Cancer research 1995;55(21):5038-42.
1995: L B Cleri; Mark G Kris; L B Tyson; Katherine M W Pisters; R A Clark; R J Gralla
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Cancer 1995;76(5):774-8.
1995: Paul J Hesketh; T Beck; M Uhlenhopp; Mark G Kris; J D Hainsworth; W G Harker; J R Cohen; E Lester; J F Kessler; D Griffen
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):2117-22.
1995: Vincent A Miller; J R Rigas; Katherine M W Pisters; Stefan C Grant; David G Pfister; Robert T Heelan; Mark G Kris
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.
American journal of clinical oncology 1995;18(4):303-6.
1995: Vincent A Miller; J R Rigas; Stefan C Grant; Katherine M W Pisters; Mark G Kris
New chemotherapeutic agents for non-small cell lung cancer.
Chest 1995;107(6 Suppl):306S-311S.
1995: Maria Rivera; Mark G Kris; R J Gralla; D A White
Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy.
American journal of clinical oncology 1995;18(3):245-50.
1995: Mark G Kris; Katherine M W Pisters; Robert J Ginsberg; J R Rigas; Vincent A Miller; Stefan C Grant; R J Gralla; Robert T Heelan; N Martini
Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2).
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S47-57.
1995: P A Francis; Mark G Kris; J R Rigas; Stefan C Grant; Vincent A Miller
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S163-72.
1995: Vincent A Miller; J R Rigas; P A Francis; Stefan C Grant; Katherine M W Pisters; Venkatraman E Seshan; K Woolley; Robert T Heelan; Mark G Kris
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Cancer 1995;75(4):968-72.
1995: J R Rigas; P A Francis; Vincent A Miller; William P Tong; Nancy Roistacher; Mark G Kris; J P Orazem; C W Young; RP Warrell
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
Cancer chemotherapy and pharmacology 1995;35(6):483-8.
1995: Stefan C Grant; Mark G Kris
New antineoplastic agents in lung cancer 1988-1993.
Cancer treatment and research 1995;72():323-47.
1994: Mark G Kris; Katherine M W Pisters; L Hinkley
Delayed emesis following anticancer chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(5):297-300.
1994: Katherine M W Pisters; Mark G Kris; R J Gralla; B Hilaris; PM McCormack; Manjit S Bains; N Martini
Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer.
Journal of surgical oncology 1994;56(4):236-41.
1994: Patricia J Hollen; Richard J Gralla; Mark G Kris; Christopher Cox
Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(4):213-22.
1994: L B Tyson; Mark G Kris; L Baltzer; Katherine M W Pisters; J R Rigas; R A Clark
Randomized phase II trial comparing two versus three doses of ondansetron when used in combination with dexamethasone in patients receiving cisplatin > or = 100 mg/m2.
American journal of clinical oncology 1994;17(3):269-72.
1994: P A Francis; J R Rigas; Mark G Kris; Katherine M W Pisters; J P Orazem; K J Woolley; Robert T Heelan
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1232-7.
1994: Mark G Kris; S M Grunberg; R J Gralla; L Baltzer; S A Zaretsky; D Lifsey; L B Tyson; L Schmidt; W F Hahne
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(5):1045-9.
1994: P J Hollen; R J Gralla; Mark G Kris; Christopher Cox; Chandra P Belani; S M Grunberg; Jeffrey Crawford; J A Neidhart
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.
Cancer 1994;73(8):2087-98.
1994: L Baltzer; Mark G Kris; L B Tyson; J R Rigas; Katherine M W Pisters
The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin.
Cancer 1994;73(3):720-3.
1994: Mark G Kris
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Important advances in oncology 1994;():165-77.
1994: Vincent A Miller; J R Rigas; J R Muindi; William P Tong; Venkatraman E Seshan; Mark G Kris; RP Warrell
Modulation of all-trans retinoic acid pharmacokinetics by liarozole.
Cancer chemotherapy and pharmacology 1994;34(6):522-6.
1993: Mark G Kris; L Baltzer; Katherine M W Pisters; L B Tyson
Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone.
Cancer 1993;72(11 Suppl):3436-42.
1993: J R Rigas; P A Francis; J R Muindi; Mark G Kris; C Huselton; F DeGrazia; J P Orazem; C W Young; RP Warrell
Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.
Journal of the National Cancer Institute 1993;85(23):1921-6.
1993: L Baltzer; Mark G Kris; L B Tyson; J R Rigas; F Vreeland; Katherine M W Pisters
Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
Cancer 1993;72(9):2695-9.
1993: L M Potanovich; Katherine M W Pisters; Mark G Kris; L B Tyson; R A Clark; L Baltzer; R J Gralla
Midazolam in patients receiving anticancer chemotherapy and antiemetics.
Journal of pain and symptom management 1993;8(8):519-24.
1993: Katherine M W Pisters; Mark G Kris; R J Gralla; M B Zaman; Robert T Heelan; N Martini
Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(9):1757-62.
1993: N Martini; Mark G Kris; B J Flehinger; R J Gralla; Manjit S Bains; ME Burt; Robert T Heelan; PM McCormack; Katherine M W Pisters; J R Rigas
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.
The Annals of thoracic surgery 1993;55(6):1365-73; discussion 1373-4.
1993: Mark G Kris; R A Clark; L B Tyson; W F Hahne; Katherine M W Pisters; R J Gralla
Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
American journal of clinical oncology 1993;16(1):77-80.
1993: J Baselga; Mark G Kris; Howard I Scher; M Phillips; Robert T Heelan
Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer.
Investigational new drugs 1993;11(1):85-6.
1993: Stefan C Grant; Mark G Kris; R J Gralla; R A Clark; L B Tyson
Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.
Cancer chemotherapy and pharmacology 1993;31(6):442-4.
1993: Mark G Kris; L B Tyson
Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 1():S30-2.
1993: Stefan C Grant; Mark G Kris; C W Young; Francis M Sirotnak
Edatrexate, an antifolate with antitumor activity: a review.
Cancer investigation 1993;11(1):36-45.
1993: Katherine M W Pisters; Mark G Kris; L B Tyson; R A Clark; R J Gralla
Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy.
Cancer 1993;71(1):226-30.
1993: Patricia J Hollen; Richard J Gralla; Mark G Kris; L M Potanovich
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 1():S51-8.
1992: J R Rigas; William P Tong; Mark G Kris; J P Orazem; C W Young; RP Warrell
Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.
Cancer research 1992;52(23):6619-23.
1992: Valerie W Rusch; Victor E Reuter; Mark G Kris; J Kurie; W H Miller; David M Nanus; A P Albino; Ethan Dmitrovsky
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.
The Journal of thoracic and cardiovascular surgery 1992;104(5):1465-9.
1992: Mark G Kris; L B Tyson; R A Clark; R J Gralla
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Cancer 1992;70(4 Suppl):1012-6.
1992: Mark G Kris
Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations.
Seminars in oncology 1992;19(4 Suppl 10):61-6.
1992: Mark G Kris
Phase II trials of ondansetron with high-dose cisplatin.
Seminars in oncology 1992;19(4 Suppl 10):23-7.
1992: S C Grant; Mark G Kris
Phase II trials in small-cell lung cancer: shouldn't we be doing better?
Journal of the National Cancer Institute 1992;84(14):1058-9.
1992: Katherine M W Pisters; Mark G Kris; L B Tyson; R A Clark; R J Gralla
Dose-ranging trial of zacopride: the emetic antiemetic?
Journal of the National Cancer Institute 1992;84(9):717-8.
1992: S C Grant; R J Gralla; Mark G Kris; J Orazem; Elizabeth Kitsis
Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):484-98.
1992: Katherine M W Pisters; Mark G Kris
Management of nausea and vomiting caused by anticancer drugs: state of the art.
Oncology (Williston Park, N.Y.) 1992;6(2 Suppl):99-104.
1992: M Rosenstein; J Armstrong; Mark G Kris; B Shank; Howard I Scher; D Fass; Louis B Harrison; Zvi Fuks; Steven Leibel
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer.
International journal of radiation oncology, biology, physics 1992;24(1):43-8.
1992: J G Armstrong; N Martini; Mark G Kris; Louis B Harrison
Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: the role of postoperative radiotherapy.
International journal of radiation oncology, biology, physics 1992;23(3):605-13.
1991: J G Armstrong; M M Rosenstein; Mark G Kris; B M Shank; Howard I Scher; D E Fass; Louis B Harrison; Steven A Leibel; Zvi Fuks
Twice daily thoracic irradiation for limited small cell lung cancer.
International journal of radiation oncology, biology, physics 1991;21(5):1269-74.
1991: J Armstrong; B Shank; Howard I Scher; Jeffrey J Gaynor; N Martini; J Kutcher; Mark G Kris
Limited small-cell lung cancer: do favorable short-term results predict ultimate outcome?
American journal of clinical oncology 1991;14(4):285-90.
1991: Jeffrey Crawford; Howard Ozer; R Stoller; D Johnson; G Lyman; I Tabbara; Mark G Kris; J Grous; V Picozzi; G Rausch
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
The New England journal of medicine 1991;325(3):164-70.
1991: J R Rigas; Mark G Kris; R J Gralla; Robert T Heelan; L D Marks
Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
Investigational new drugs 1991;9(2):187-90.
1991: M Z Berger; Mark G Kris; R J Gralla; L D Marks; L M Potanovich; J J Dimaggio; Robert T Heelan
Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
American journal of clinical oncology 1991;14(2):124-6.
1991: J G Armstrong; M M Rosenstein; Howard I Scher; D E Fass; Michael J Zelefsky; Mark G Kris
Limited small cell lung cancer: prognostic significance of a complete response to the induction phase of chemotherapy followed by thoracic irradiation.
Radiology 1991;178(3):875-8.
1991: Chaitanya R Divgi; Sydney Welt; Mark G Kris; Francisco X Real; Samuel D J Yeh; R Gralla; B Merchant; S Schweighart; M Unger; Steven M Larson
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.
Journal of the National Cancer Institute 1991;83(2):97-104.
1991: Maurie Markman; R D'Acquisto; N Iannotti; Mark G Kris; T Hakes; Dean F Bajorin; George J Bosl; B Reichman; E Casper; G Magill
Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate.
Journal of cancer research and clinical oncology 1991;117(2):151-5.
1991: R J Gralla; R A Clark; Mark G Kris; L B Tyson
Methodology in anti-emetic trials.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 1():S5-8; discussion S22.
1990: Josep Dalmau; Henry Furneaux; R J Gralla; Mark G Kris; Jerome B Posner
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.
Annals of neurology 1990;27(5):544-52.
1989: L B Tyson; R J Gralla; Mark G Kris; C W Young; R A Clark
Dose-ranging antiemetic trial of high-dose oral metoclopramide.
American journal of clinical oncology 1989;12(3):239-43.
1989: R A Clark; L B Tyson; R J Gralla; Mark G Kris
Antiemetic therapy: management of chemotherapy-induced nausea and vomiting.
Seminars in oncology nursing 1989;5(2 Suppl 1):53-7.
1989: Mark G Kris; R W D'Acquisto; R J Gralla; M T Burke; L D Marks; M P Fanucchi; Robert T Heelan
Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
American journal of clinical oncology 1989;12(1):24-6.
1989: Mark G Kris; R J Gralla; R A Clark; L B Tyson
Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.
Journal of the National Cancer Institute 1989;81(1):42-6.
1989: Mark G Kris; R J Gralla; L B Tyson; R A Clark; C Cirrincione; S Groshen
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):108-14.
1988: Mark G Kris; J J Kinahan; R J Gralla; M P Fanucchi; Michael S Wertheim; J P O'Connell; L D Marks; L Williams; F Farag; C W Young
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Cancer research 1988;48(19):5573-9.
1988: R J Gralla; Mark G Kris
Chemotherapy in non-small cell lung cancer: results of recent trials.
Seminars in oncology 1988;15(3 Suppl 4):2-5.
1988: Mark G Kris; R J Gralla; R A Clark; L B Tyson; S Groshen
Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: a randomized trial with placebo in patients receiving cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):663-8.
1988: Mark G Kris; R J Gralla; R A Clark; L B Tyson
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):659-62.
1988: N Martini; Mark G Kris; R J Gralla; Manjit S Bains; PM McCormack; Larry R Kaiser; ME Burt; M B Zaman
The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0).
The Annals of thoracic surgery 1988;45(4):370-9.
1988: K Y Shum; Mark G Kris; R J Gralla; M T Burke; L D Marks; Robert T Heelan
Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(3):446-50.
1988: R J Gralla; Mark G Kris; L B Tyson; R A Clark
Controlling emesis in patients receiving cancer chemotherapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1988;108():89-101.
1988: Mark G Kris
Peaks, valleys, and plateaus in small cell lung cancer.
Cancer investigation 1988;6(6):743-4.
1988: Howard I Scher; R Gralla; L Linares; Mark G Kris; Robert T Heelan; B Shank
Preliminary results of combination chemotherapy and sequential accelerated fractionation radiation therapy in limited-stage small cell carcinoma of the lung. Evaluation of measures for reduction of toxicity and effect on complete response rate.
Antibiotics and chemotherapy 1988;41():184-9.
1987: Mark G Kris; R J Gralla; R A Clark; L B Tyson; S Groshen
Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.
Cancer 1987;60(11):2816-22.
1987: Mark G Kris; R J Gralla; N Martini; L V Stampleman; M T Burke
Preoperative and adjuvant chemotherapy in locally advanced non-small cell lung cancer.
The Surgical clinics of North America 1987;67(5):1051-9.
1987: Mark G Kris; R J Gralla; M T Burke; J J Fiore; David P Kelsen; L D Marks; Robert T Heelan
Phase II trial of esorubicin in patients with advanced non-small cell lung cancer.
Cancer treatment reports 1987;71(7-8):783-4.
1987: Mark G Kris; R J Gralla; M T Burke; L D Berkowitz; L D Marks; David P Kelsen; Robert T Heelan
Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer.
Cancer treatment reports 1987;71(7-8):763-4.
1987: D A White; Mark G Kris; D E Stover
Bronchoalveolar lavage cell populations in bleomycin lung toxicity.
Thorax 1987;42(7):551-2.
1987: D A White; L S Schwartzberg; Mark G Kris; George J Bosl
Acute chest pain syndrome during bleomycin infusions.
Cancer 1987;59(9):1582-5.
1987: R J Gralla; L B Tyson; Mark G Kris; R A Clark
The management of chemotherapy-induced nausea and vomiting.
The Medical clinics of North America 1987;71(2):289-301.
1986: J P O'Connell; Mark G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; David P Kelsen; Robert T Heelan; R B Golbey
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(11):1604-14.
1986: Mark G Kris; R J Gralla; Michael S Wertheim; David P Kelsen; J P O'Connell; M T Burke; J J Fiore; I R Cibas; Robert T Heelan
Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
Cancer treatment reports 1986;70(9):1091-6.
1986: Mark G Kris; J P O'Connell; R J Gralla; Michael S Wertheim; R M Parente; P B Schiff; C W Young
Phase I trial of taxol given as a 3-hour infusion every 21 days.
Cancer treatment reports 1986;70(5):605-7.
1986: Mark G Kris; S D Yeh; R J Gralla; C W Young
Simultaneous estimation of liquid and solid gastric emptying using radiolabelled egg and water in supine normal subjects.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1986;13(6):629-31.
1985: L B Tyson; R J Gralla; R A Clark; Mark G Kris; L A Bordin; George J Bosl
Phase 1 trial of levonantradol in chemotherapy-induced emesis.
American journal of clinical oncology 1985;8(6):528-32.
1985: Mark G Kris; R J Gralla; R A Clark; L B Tyson; J J Fiore; David P Kelsen; S Groshen
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
Cancer treatment reports 1985;69(11):1257-62.
1985: Mark G Kris; R J Gralla; R A Clark; L B Tyson; J P O'Connell; Michael S Wertheim; David P Kelsen
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(10):1379-84.
1985: Mark G Kris; R J Gralla; David P Kelsen; E S Casper; M T Burke; J J Fiore; I R Cibas; Robert T Heelan
Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
American journal of clinical oncology 1985;8(5):377-9.
1985: Mark G Kris; R J Gralla; L A Kalman; David P Kelsen; E S Casper; M T Burke; S Groshen; I R Cibas; R Bagin; Robert T Heelan
Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.
Cancer treatment reports 1985;69(4):387-95.
1985: Mark G Kris; R J Gralla; David P Kelsen; E S Casper; M T Burke; J J Fiore; I R Cibas; Robert T Heelan
Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment.
Chest 1985;87(3):368-72.
1985: Mark G Kris; R J Gralla; L B Tyson; R A Clark; David P Kelsen; L K Reilly; S Groshen; George J Bosl; L A Kalman
Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.
Cancer 1985;55(3):527-34.
1985: Mark G Kris; R Mertelsmann; Suresh C Jhanwar; Raju S K Chaganti; T H Szatrowski; T S Gee; Z Arlin; Sanford J. Kempin; Pasquale Benedetto; Bayard Clarkson
Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia.
Leukemia research 1985;9(10):1231-5.
1984: Mark G Kris; D Pablo; R J Gralla; M T Burke; J Prestifilippo; D Lewin
Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy.
Cancer treatment reports 1984;68(7-8):1029-31.
1984: R J Gralla; L B Tyson; L A Bordin; R A Clark; David P Kelsen; Mark G Kris; L B Kalman; S Groshen
Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.
Cancer treatment reports 1984;68(1):163-72.
1983: L A Kalman; R J Gralla; E S Casper; Mark G Kris; C Gordon; T M Woodcock
Phase I trial of PCNU.
Cancer treatment reports 1983;67(11):1027-9.
1983: L A Kalman; M B Stoopler; E S Casper; David P Kelsen; Mark G Kris; R J Gralla
Phase II trial of PCNU in non-small cell lung cancer.
Cancer treatment reports 1983;67(9):837.
1983: Mark G Kris; L B Tyson; R J Gralla; R A Clark; J C Allen; L K Reilly
Extrapyramidal reactions with high-dose metoclopramide.
The New England journal of medicine 1983;309(7):433-4.
1983: Mark G Kris; R J Gralla; L B Tyson; R A Clark
Antiemetics and cytotoxic drugs.
British medical journal (Clinical research ed.) 1983;287(6388):363-4.
1983: L A Kalman; Mark G Kris; R J Gralla; David P Kelsen; E S Casper; Robert T Heelan; R E Wittes
Phase II trial of 4'-epi-doxorubicin in patients with non-small cell lung cancer.
Cancer treatment reports 1983;67(6):591-2.
1982: Richard H Moseley; Mark G Kris; A Einzig; R West; T S Gee; D Armstrong
Respiratory alkalosis and abdominal pain heralding Candida hepatitis: occurrence in patients with acute leukemia in remission.
Archives of internal medicine 1982;142(8):1495-7.